Suryakant Jaiswal¹, V Ramya Shri², Nidhi Soni¹, Rohit Singh², Tanu Sahu¹, Himani Netam¹, Shruti² and Gyanesh Kumar Sahu²*

¹Rungta Institute of Pharmaceutical Sciences Kohka, Bhilai, India
²Rungta Institute of Pharmaceutical Sciences and Research Kohka, Bhilai, India

*Corresponding Author: Gyanesh Kumar Sahu, Professor and Dean, Rungta Institute of Pharmaceutical Sciences and Research, Kohka, Kurud, Bhilai, India.

Received: March 24, 2025; Published: April 10, 2025

The potential of the broad-spectrum tetracycline antibiotic doxycycline to treat and prevent malaria has been investigated, especially when combined with other antimalarial medications. This study examines the pharmacodynamics, clinical effectiveness, possible advantages, difficulties, and new resistance patterns related to the use of doxycycline to treat malaria. Doxycycline's changing function in malaria prevention and the treatment of both severe and uncomplicated malaria is examined. Its significance in treating Plasmodium falciparum, the most prevalent and severe malaria parasite, which is resistant to many drugs, is given particular emphasis. Doxycycline has been used in medicine for almost 40 years and belongs to the tetracycline class of antibiotics. It is a bacteriostatic medication that is well tolerated and works by blocking bacterial ribosomes. Usually, a dosage of 100 mg per day or twice daily is used. It has typically strong tissue penetration and is well absorbed. When renal or hepatic impairment is present, the dose does not need to be changed because the serum half-life is 18–22 hours. It is typically contraindicated in pregnancy or infancy due to worries about discoloration of developing teeth and possible effects on growing bones. The main adverse effects are gastrointestinal and dermatological.

Keywords: Broad-Spectrum; Doxycycline; Plasmodium; Medication; Bacteriostatic.

References

1. Meshnick S R., et al. “Antimalarial mechanisms of doxycycline”. Antimicrobial Agents and Chemotherapy3 (1996): 786-791.
2. White N J. “Qinghaosu (artemisinin): the yellow flower and the future of malaria treatment”. The Lancet9620 (2008): 1051-1053.
3. Nosten F., et al. “Doxycycline in the treatment of uncomplicated falciparum malaria in Southeast Asia”. The Lancet9516 (2021): 1552-1558.
4. Chopra I and Roberts M. “Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance”. Microbiology and Molecular Biology Reviews 65 (2001): 232-260.
5. Batty KT., et al. “Pharmacodynamics of doxycycline in a murine malaria model”. Antimicrobial Agents and Chemotherapy 51 (2007): 4477-4479.
6. Ramamurthy NS., et al. “Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines”. Journal of Periodontology 73 (2002): 726-734.
7. Deppermann KM., et al. “Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid”. Antimicrobial Agents and Chemotherapy 33 (1989): 1901-1907.
8. Colmenero JD., et al. “Possible implications of doxycycline-rifampin interaction for treatment of brucellosis”. Antimicrobial Agents and Chemotherapy 38 (1994): 2798-802.
9. Neuvonen PJ., et al. “Effect of antiepileptic drugs on the elimination of various tetracycline derivatives”. European Journal of Clinical Pharmacology 9 (1975): 147-154.
10. San Gabriel P., et al. “Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis”. Antimicrobial Agents and Chemotherapy 48 (2004): 168-171.
11. Morrissey I., et al. “Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods”. Journal of Antimicrobe and Chemotherapy 55 (2005): 200-208.
12. Workowski KA., et al. “Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies”. Annals of Internal Medicine 148 (2008): 606-613.
13. Lau CY and Qureshi AK. “Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials”. Sexually Transmitted Diseases 29 (2002): 497-502.
14. Skerk V., et al. “Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis”. International Journal of Antimicrobial Agents 24 (2004): 188-191.
15. Lai CH., et al. “Clinical characteristics of acute Q fever, scrub typhus, and murine typhus with delayed defervescence despite doxycycline treatment”. American Journal of Tropical Medicine and Hygiene 79 (2008): 441-446.
16. Rolain JM., et al. “Recommendations for treatment of human infections caused by Bartonella species”. Antimicrobial Agents and Chemotherapy 48 (2004): 1921-1933.
17. https://doi.org/10.4137/CMT.S2035
18. Speer BS., et al. “Evidence that a novel tetracycline resistance gene found on two Bacteroides transposons encodes an NADP requiring oxidoreductase”. Journal of Bacteriology 173 (1991): 176-183.
19. Karlsson M., et al. “Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis”. Neurology 44 (1994): 1203-1207.
20. Ljostad U., et al. “Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial”. Lancet Neurology 7 (2008): 690-695.
21. Wallace RJ Jr., et al. “Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria”. Antimicrobial Agents and Chemotherapy 46 (2002): 3164-3167.
22. https://www.indiamart.com/proddetail/antimalarial-injection-for-maleria-20700818648.html
23. Koeth LM., et al. “Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/ clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000”. International Journal of Infectious Diseases 8 (2004): 362-373.
24. Suputtamongkol Y., et al. “An open, randomized, controlled trial of penicillin, doxycycline, and cefotaxime for patients with severe leptospirosis”. Clinical Infectious Diseases 39 (2004): 1417-1424.
25. Bachelez H., et al. “The use of tetracyclines for the treatment of sarcoidosis”. Archives of Dermatology 137 (2001): 69-73.
26. Hasanjani Roushan MR., et al. “Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans”. Clinical Infectious Diseases 42 (2006): 1075-1080.
27. Kucers A., et al. “Tetracyclines”. In: The use of antibiotics. A clinical review of antibacterial, antifungal and antiviral drugs. 5th ed: Oxford: Butterworth-Heinemann (1997).

Citation

Citation: Gyanesh Kumar Sahu., et al. “A Review of Doxycycline-Based Malaria Treatment Regimens: Efficacy, Safety, and Resistance Patterns" Acta Scientific Pharmaceutical Sciences 9.5 (2025): 13-17.

Copyright

Copyright: © 2025 Gyanesh Kumar Sahu., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.